[Incidence and reasons of premature discontinuation of abacavir: results of a hospital investigation among 628 patients]. / Incidence et motifs des arrêts prématurés de l'abacavir au cours des deux premiers mois de traitement: résultats d'une enquête hospitalière chez 628 patients.

OBJECTIVE: The aim of this study was to determine the incidence of abacavir discontinuation within the first two months of treatment and the link with a true hypersensitivity reaction (HSR). PATIENTS AND METHODS: A retrospective study was made between January 1998 and January 2006 on a cohort of HIV positive patients treated by abacavir delivered by the Bordeaux Saint-André University Hospital pharmacy. RESULTS: Six hundred (and) twenty-eight patients were included. The reasons for non-renewal of abacavir prescription within the first three months of treatment were investigated. Early discontinuation for adverse effects was reported in 32 patients (5.1%): proved diagnosis of HSR (N=10), uncertain diagnosis of HSR (N=8), and no HSR (N=14). The decision for discontinuation was taken by physician after consultation in 76% of cases.